Detection of cathepsin B, cathepsin L, cystatin C, urokinase plasminogen activator and urokinase plasminogen activator receptor in the sera of lung cancer patients

Chen,Qingyong; Fei,Jun; Wu,Lijun; Jiang,Zhongyong; Wu,Yuquan; Zheng,Yun; Lu,Guohua

doi:10.3892/ol.2011.302

Detection of cathepsin B, cathepsin L, cystatin C, urokinase plasminogen activator and urokinase plasminogen activator receptor in the sera of lung cancer patients

Authors:
- Qingyong Chen
- Jun Fei
- Lijun Wu
- Zhongyong Jiang
- Yuquan Wu
- Yun Zheng
- Guohua Lu
View Affiliations

Affiliations: Department of Respiratory Disease, The 117th Hospital of PLA, Zhejiang 310013, P.R. China, Department of Respiratory Disease, First Affiliated Hospital, College of Medicine, Zhejiang University, Zhejiang 310004, P.R. China
Published online on: May 11, 2011 https://doi.org/10.3892/ol.2011.302
Pages: 693-699

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to determine the levels of cathepsin B (cath B), cathepsin L (cath L), cystatin C, urokinase plasminogen activator (u-PA) and urokinase plasminogen activator receptor (u-PAR) in the sera of patients with lung cancer compared to healthy controls using ELISA. Concomitantly, the relationship between the components and clinicopathological prognosis was analyzed. The study included 30 healthy volunteers and 105 lung cancer patients. Blood samples were collected and cath B, cath L, cystatin C, u-PA and u-PAR measurements were made using ELISA. Results showed that the levels of cath B, cath L, cystatin C, u-PA and u-PAR were significantly higher in the patient group compared to the healthy controls. The significance was marked for cath B and mild for u-PAR in correlation with lymph node metastasis. There was no significance for other parameters. Notably, patients with a combination of high cystatin C and high cath B levels had significantly lower survival probability as compared to those with cystatin C+/cath B- or with cystatin C-/cath B-. Similarly, patients with a combination of high u-PA and u-PAR experienced significantly shorter survival. Furthermore, the univariate analysis revealed that cath B, u-PAR, lymph node metastases, stage and grade were related to survival. However, findings of the multivariate Cox analysis indicated that the sera levels of cath B, u-PAR and lymph node metastases may serve as independent prognostic variables in patients with lung cancer.

View Figures

View References

1	Sloane BF, Herman CJ and Padarathsingh M: Molecular mechanisms of progression and metastasis of human tumors: a pathology B study section workshop. Working Report from the Division of Research Grants. NIH Cancer Res. 54:5241–5245. 1994.PubMed/NCBI
2	Thomssen C, Schmitt M, Goretzki L, et al: Prognostic value of the cysteine proteases cathepsins B and cathepsin L in human breast cancer. Clin Cancer Res. 1:741–746. 1995.PubMed/NCBI
3	Kos J, Stabuc B, Schweiger A, et al: Cathepsins B, H, and L and their inhibitors stefin A and cystatin C in sera of melanoma patients. Clin Cancer Res. 3:1815–1822. 1997.PubMed/NCBI
4	Kayser K, Richter N, Hufnagl P, Kayser G, Kos J and Werle B: Expression, proliferation activity and clinical significance of cathepsin B and cathepsin L in operated lung cancer. Anticancer Res. 23:2767–2772. 2003.PubMed/NCBI
5	Kos J and Lah TT: Cysteine proteinases and their endogenous inhibitors: Target proteins for prognosis, diagnosis and therapy in cancer (Review). Oncol Rep. 5:1349–1361. 1998.PubMed/NCBI
6	Kos J, Werle B, Lah T and Brunner N: Cysteine proteinases and their inhibitors in extracellular fluids: markers for diagnosis and prognosis in cancer. Int J Biol Markers. 15:84–89. 2000.PubMed/NCBI
7	Krepela E, Prochazka J, Karova B, Cermak J and Roubkova H: Cysteine proteases and cysteine protease inhibitors in non-small cell lung cancer. Neoplasma. 45:318–331. 1998.PubMed/NCBI
8	Andreasen PA, Kjoller L, Christensen L and Duffy MJ: The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer. 72:1–22. 1997. View Article : Google Scholar : PubMed/NCBI
9	Pedersen H, Grondahl-Hansen J, Francis D, et al: Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res. 54:120–123. 1994.PubMed/NCBI
10	Pedersen H, Brunner N, Francis D, et al: Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res. 54:4671–4675. 1994.PubMed/NCBI
11	Kos J, Smid A, Krasovec M, et al: Lysosomal proteases cathepsins D, B, H, L and their inhibitors stefins A and B in head and neck cancer. Biol Chem Hoppe Seyler. 376:401–405. 1995. View Article : Google Scholar : PubMed/NCBI
12	Schmitt M, Janicke F, Moniwa N, Chucholowski N, Pache L and Graeff H: Tumor-associated urokinase-type plasminogen activator: biological and clinical significance. Biol Chem Hoppe Seyler. 373:611–622. 1992. View Article : Google Scholar : PubMed/NCBI
13	Sukoh N, Abe S, Ogura S, et al: Immunohistochemical study of cathepsin B. Prognostic significance in human lung cancer. Cancer. 74:46–51. 1994. View Article : Google Scholar : PubMed/NCBI
14	Kos J, Nielsen HJ, Krasovec M, et al: Prognostic values of cathepsin B and carcinoembryonic antigen in sera of patients with colorectal cancer. Clin Cancer Res. 4:1511–1516. 1998.PubMed/NCBI
15	Fujise N, Nanashim A, Taniguchi Y, et al: Prognostic impact of cathepsin B and matrix metalloproteinase-9 in pulmonary adenocarcinomas by immunohistochemical study. Lung Cancer. 27:19–26. 2000. View Article : Google Scholar : PubMed/NCBI
16	Werle B, Kraft C, Lah TT, et al: Cathepsin B in infiltrated lymph nodes is of prognostic significance for patients with nonsmall cell lung carcinoma. Cancer. 89:2282–2291. 2000. View Article : Google Scholar
17	Cordes C, Bartling B, Simm A, et al: Simultaneous expression of Cathepsins B and K in pulmonary adenocarcinomas and squamous cell carcinomas predicts poor recurrence-free and overall survival. Lung Cancer. 64:79–85. 2009. View Article : Google Scholar : PubMed/NCBI
18	Cox JL, Sexton PS, Green TJ and Darmani NA: Inhibition of B16 melanoma metastasis by overexpression of the cysteine proteinase inhibitor cystatin C. Melanoma Res. 9:369–374. 1999. View Article : Google Scholar : PubMed/NCBI
19	Kos J, Krasovec M, Cimerman N, Nielsen HJ, Christensen IJ and Brunner N: Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: relation to prognosis. Clin Cancer Res. 6:505–511. 2000.PubMed/NCBI
20	Robert C, Bolon I, Gazzeri S, Veyrenc S, Brambilla C and Brambilla E: Expression of plasminogen activator inhibitors 1 and 2 in lung cancer and their role in tumor progression. Clin Cancer Res. 5:2094–2102. 1999.PubMed/NCBI
21	Salden M, Splinter TA, Peters HA, et al: The urokinase-type plasminogen activator system in resected non-small-cell lung cancer. Rotterdam Oncology Thoracic Study Group. Ann Oncol. 11:327–332. 2000. View Article : Google Scholar : PubMed/NCBI
22	Almasi CE, Hoyer-Hansen G, Christensen IJ and Pappot H: Prognostic significance of urokinase plasminogen activator receptor and its cleaved forms in blood from patients with non-small cell lung cancer. Acta Pathol Microbiol Immunol Scand Suppl. 117:755–761. 2009. View Article : Google Scholar : PubMed/NCBI
23	Corticchiato O, Cajot JF, Abrahamson M, Chan SJ, Keppler D and Sordat B: Cystatin C and cathepsin B in human colon carcinoma: expression by cell lines and matrix degradation. Int J Cancer. 52:645–652. 1992. View Article : Google Scholar : PubMed/NCBI